Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2013, Article ID 792526, 4 pages
http://dx.doi.org/10.1155/2013/792526
Case Report

The Efficacy and Safety of Rituximab in a Patient with Rheumatoid Spondylitis

1Department of Rheumatology, Faculty of Medicine, Şifa University, Bornova, 35100 Izmir, Turkey
2Department of Orthopaedic Surgery, Faculty of Medicine, Şifa University, Bornova, 35100 Izmir, Turkey
3Department of Rheumatology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey

Received 19 August 2013; Accepted 30 September 2013

Academic Editors: M. Salazar-Paramo, G. J. Tsay, and A. Zoli

Copyright © 2013 Şenol Kobak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Braun and J. Sieper, “Ankylosing spondylitis,” The Lancet, vol. 369, no. 9570, pp. 1379–1390, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. E. L. Matteson, M. D. Cohen, and D. L. Conn, “Rheumatoid arthritis: clinical features and systemic involvement,” in Rheumatology, J. H. Klippel and P. A. Dieppe, Eds., vol. 1, section 5.4.2, Mosby, London, UK, 1992. View at Google Scholar
  3. J. Zochling, D. van der Heijde, R. Burgos-Vargas et al., “ASAS/EULAR recommendations for the management of ankylosing spondylitis,” Annals of the Rheumatic Diseases, vol. 65, no. 4, pp. 442–452, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Emery, R. Fleischmann, A. Filipowicz-Sosnowska et al., “Rituximab in rheumatoid arthritis: a double-blind, placebo-controlled, dose-ranging trial,” Arthritis and Rheumatism, vol. 52, article 1917, 2005. View at Google Scholar
  5. T. Jónsdóttir, I. Gunnarsson, A. Risselada, E. W. Henriksson, L. Klareskog, and R. F. Van Vollenhoven, “Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response,” Annals of the Rheumatic Diseases, vol. 67, no. 3, pp. 330–334, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Seo, U. Specks, and K. A. Keogh, “Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations,” Journal of Rheumatology, vol. 35, no. 10, pp. 2017–2023, 2008. View at Google Scholar · View at Scopus
  7. D. Wendling and E. Toussirot, “Anti-TNF-α therapy in ankylosing spondylitis,” Expert Opinion on Pharmacotherapy, vol. 5, no. 7, pp. 1497–1507, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Braun, M. Bollow, L. Neure et al., “Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis,” Arthritis and Rheumatism, vol. 38, no. 4, pp. 499–505, 1995. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Bollow, T. Fischer, H. Reißhauer et al., “Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis—cellularity correlates with the degree of enhancement detected by magnetic resonance imaging,” Annals of the Rheumatic Diseases, vol. 59, no. 2, pp. 135–140, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Appel, C. Loddenkemper, Z. Grozdanovic et al., “Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis,” Arthritis Research and Therapy, vol. 8, no. 5, article R143, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. I.-H. Song, F. Heldmann, M. Rudwaleit et al., “Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial,” Arthritis and Rheumatism, vol. 62, no. 5, pp. 1290–1297, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Rodríguez-Escalera and A. Fernández-nebro, “The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B,” Rheumatology, vol. 47, no. 11, pp. 1732–1733, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Nocturne, M. Dougados, A. Constantin, C. Richez, J. Sellam, and A. Simon, “Lack of efficacy of rituximab in spondyloarthropathies:data of 8 patients prospectively followed in the French AIR (‘Auto-Immunity and Rituximab’) registry,” Annals of the Rheumatic Diseases, vol. 68, supplement 3, p. 626, 2009. View at Google Scholar
  14. S. K. Schleenbecker and K. Strock Muller, “Improvement of refractory ankylosing spondylitis in response to rituximab: a case report,” Annals of the Rheumatic Diseases, vol. 67, supplement 2, p. 626, 2008. View at Google Scholar
  15. D. Wendling, B. Augé, G. Streit, E. Toussirot, and S. Mathieu, “Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis,” Joint Bone Spine, vol. 75, no. 4, pp. 510–511, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Toussaint, S. Karrer, and S. Wassenberg, “Successful treatment of neutrophilic granulomatous dermatitis with rituximab in a patient with rheumatoid arthritis and spondylitis ancylosans: a case report,” Annals of the Rheumatic Diseases, vol. 67, supplement 2, p. 317, 2008. View at Google Scholar
  17. T. Dörner and G. R. Burmester, “New approaches of B-cell-directed therapy: beyond rituximab,” Current Opinion in Rheumatology, vol. 20, no. 3, pp. 263–268, 2008. View at Publisher · View at Google Scholar · View at Scopus